Issue

Vol. 64 No. 5: Issue 5

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

Immunoexpression of progesterone receptor, epithelial growth factor receptor and galectin-3 in uterine smooth muscle tumors

https://doi.org/10.14715/cmb/2018.64.5.2
Mervat M. Soltan
Department of Pathology, Faculty of Medicine, Taibah University, Almadina, KSA
Abdelkader Mohammed Albasry
Department of Pathology, Faculty of Medicine, Taibah University, Almadina, KSA
Maha K. Eldosouky
Department of Anatomy, Faculty of Medicine, Taibah University, Almadina, KSA
Hanan S. Abdelhamid
Department of Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt

Corresponding Author(s) : Maha K. Eldosouky

mahadesouky7@gmail.com

Cellular and Molecular Biology, Vol. 64 No. 5: Issue 5

Abstract

Uterine smooth muscle tumors constitute a spectrum of neoplasms. Diagnosis of leiomyomas (LMs) is usually straight forwards; however, atypical leiomyomas (ALMs) and smooth muscle tumors of uncertain malignant potential (STUMPs) have overlapping features and need to be distinguished from leiomyosarcoma. To evaluate progesterone receptor (PR), epithelial growth factor receptor (EGF-R), and galectin-3 expression in LMs, ALMs, STUMPs, and leiomyosarcomas and to assess their possible role in differentiating those tumors. Immunoexpression of EGF-R, PR, and galectin-3 were studied in 44 cases of uterine smooth muscle tumors through retrospective study. Studied cases included 20 LM, 9 ALM, 5 STUMP, and 10 leiomyosarcomas. A semiquantitative score was used to evaluate immunohistochemical staining. EGF-R overexpression was detected in leiomyosarcomas while a lack of or reduced EGF-R expression was observed in the nonsarcomatous group (LMs, ALMs, and STUMPs) with a highly significant difference. On the contrary, there was weak or negative PR staining in leiomyosarcomas compared to intense PR expression in the nonsarcomatous group with a highly significant difference. Meanwhile, galectin-3 was downregulated in leiomyosarcomas compared to the nonsarcomatous group with a significant difference. Correlation analysis revealed negative correlation between EGF-R and PR expression with significant statistical results while correlation of galectin-3 with EGF-R and PR showed insignificant statistical results. Immunoexpression of EGF-R, PR, and galectin-3 could help differentiate challenging cases of uterine smooth muscle tumors. Further studies are recommended to investigate interactions between EGF-R, PR, and galectin-3 and to plan new therapeutic strategies.

Keywords

Leiomyoma. Receptor Progesterone Galectin 3.
Soltan, M. M., Albasry, A. M., Eldosouky, M. K., & Abdelhamid, H. S. (2018). Immunoexpression of progesterone receptor, epithelial growth factor receptor and galectin-3 in uterine smooth muscle tumors. Cellular and Molecular Biology, 64(5), 7–12. https://doi.org/10.14715/cmb/2018.64.5.2
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Hewedi I H, Radwan N A, Shahs L S. Diagnostic value of progesterone receptor and p53 expression in uterine smooth muscle tumors. Diagnostic Pathology. 2012; 7(1):1.
  2. Chow K L, Tse K Y, Cheung C L, et al. The mitosis"specific marker phosphohistone"H3 (PHH3) is an independent prognosticator in uterine smooth muscle tumors: An outcome"based study. Histopathology. 2017; 70(5): "746-755.
  3. Deodhar K K, Goyal P, Rekhi B, et al. Uterine smooth muscle tumors of uncertain malignant potential and atypical leiomyoma: A morphological study of these grey zones with clinical correlation. Indian J Pathol Microbiol. 2011; 54 (4): 706-711.
  4. íœnver N U, Acikalin M F, í–ner íœ, Ciftci E, Ozalp S S, Colak E. Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors. Arch Gynecol Obstet. 2011; 284(2): 483-490.
  5. Marsh E E, Bulun S E. Steroid hormones and leiomyomas. Obstet Gyncecol Clin North Am. 2006; 33 (1): 59-67.
  6. Yu L, Moore A B, Dixon D. Receptor tyrosine kinases and their hormonal regulation in uterine leiomyoma. Seminars in Reproductive Medicine. 2010; 28(3): 250–259.
  7. Brustmann H. Epidermal growth factor receptor expression in serous ovarian carcinoma: An immunohistochemical study with galectin-3 and cyclin D1 and outcome. Int J Gynecol Pathol. 2008; 27(3): 380-389.
  8. Dondoo T O, Fukumori T, Daizumoto K, et al. Galectin-3 Is implicated in tumor progression and resistance to anti-androgen drug through regulation of androgen receptor signaling in prostate cancer. Anticancer Res. 2017; 37(1): 125-134."
  9. Merlin J, Stechly L, De Beauce S, et al. Galectin-3 regulates MUC1 and EGFR cellular distribution and EGFR downstream pathways in pancreatic cancer cells. Oncogene. 2011; 30(22): 2514-2525.
  10. Song L, Tang J W, Owusu L, Sun M Z, Wu J, Zhang J. Galectin-3 in cancer. Clin Chim Acta. 2014; 431: 185-191.
  11. Thijssen V L, Heusschen R, Caers J, Griffioen A W. Galectin expression in cancer diagnosis and prognosis: A systematic review. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2015; 1855(2): 235-247.
  12. Rago T, Scutari M, Loiacono V, et al. Low elasticity of thyroid nodules on ultrasound elastography is correlated with malignancy, degree of fibrosis, and high expression of galectin-3 and fibronectin-1. Thyroid.2017; 27(1): 103-110."
  13. Weissenbacher T, Vrekoussis T, Roeder D, et al. Analysis of epithelial growth factor-receptor (EGFR) phosphorylation in uterine smooth muscle tumors: Correlation to mucin-1 and galectin-3 expression. Inernational Journal of Molecular Sciences. 2013; 14(3): 4783–4792.
  14. Zaloudek C J, Hendrickson M R, Soslow R A. Mesenchymal tumors of the uterus. In: Kurman R J, Ellenson L H, Ronnett B M, eds. Blaustein's pathology of the female genital tract. 6th ed. New York: Springer. 2011; 453-527.
  15. Jeschke U, Mylonas I, Shabani N, et al. Expression of sialyllewis X, sialyl Lewis a, E-cadherin and cathepsin-D in human breast cancer: Immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis. Anticancer Res. 2005; 25(3A): 1615-1622."
  16. Mylonas I, Makovitzky J, Jeschke U, Briese V, Friese K, Gerber B. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma in situ (DCIS) versus invasive breast cancer alone. Anticancer Res. 2005; 25(3A): 1719-1723.
  17. Anderson S E, Nonaka D, Chuai S, et al. p53, epidermal growth factor, and platelet -derived growth factor in uterine leiomyosarcoma and leiomyomas. International Journal of Gynecological Cancer. 2006; 16(2): 849-853."
  18. Jeschke U, Kuhn C, Mylonas I, et al. Development and characterization of monoclonal antibodies for the immunohistochemical detection of glycodelin A in decidual, endometrial and gynaecological tumour tissues. Histopathology. 2006; 48(4): 394-406.
  19. Sanci M, Dikis C, Inan S, Turkoz E, Dicle N, Ispahi C. Immunolocalization of VEGF, VEGF receptors, EGF-R and Ki-67 in leiomyoma, cellular leiomyoma and leiomyosarcoma. Acta Histochem. 2011; 113(3): 317-325.
  20. Ishikawa H, Ishi K, Serna V A, Kakazu R, Bulun S E, Kurita T. Progesterone is essential for maintenance and growth of uterine leiomyoma. Endocrinology. 2010; 151(6): 2433-2442."
  21. Kim J J, Sefton E. C. The role of progesterone signaling in the pathogenesis of uterine leiomyoma. Molecular and Cellular Endocrinology. 2012; 358(2): 223-231."
  22. Kim J J, Kurita T, Bulun S E. Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr Rev. 2013; 34(1): 130-162.
  23. Mozzachio K, Moore A B, Kissling G E, Dixon D. Immunoexpression of steroid hormone receptors and proliferation markers in uterine leiomyoma and normal myometrial tissues from the miniature pig, Susscrofa. Toxicol Pathol. 2016; 44(3):450-457.
  24. Mittal K, Demopoulos RI. MIB-1 (Ki-67), p53, estrogen receptor and progesterone receptor expression in uterine smooth muscle tumors. Hum Pathol. 2001; 32 (9): 984-987.
  25. Bodner K, Bodner-Adler B, Kimberger O, Czerwenka K, Mayerhofer K. Estrogen and progesterone receptor expression in patients with uterine smooth muscle tumors. Fertil Steril. 2004; 81 (4): 1062-1066.
  26. Gökaslan H, Turkeri L, Kavak ZN, et al. Differential diagnosis of smooth muscle tumors utilizing p53, pTEN and Ki-67 expression with estrogen and progesterone receptors. Gynecol Obstet Invest. 2005; 59 (1): 36-40.
  27. Watanabe K, Suzuki T. Uterine leiomyoma versus leiomyosarcoma: A new attempt at differential diagnosis based on their cellular characteristics. Histopathology. 2006; 48(5): 563-568."
  28. Stćƒnescu A D, Nistor E, Sajin M, Stepan A E. Immunohistochemical analysis in the diagnosis of uterine myometrial smooth muscle tumors. Rom J Morphol Embryol. 2014; 55(3 Suppl): 1129-1136.
  29. Liang Y, Zhang X, Chen X, Lü W. Diagnostic value of progesterone receptor, p16, p53 and pHH3 expression in uterine atypical leiomyoma. International Journal of Clinical and Experimental Pathology. 2015; 8(6): 7196-7202.
  30. Khelwatty S, Essapen S, Bagwan I, Green M, Seddon A, Modjtahedi H. The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer. Oncotarget. 2017; 8(5):7666-7677.
  31. Moore A B, He H, Yoshida A, Rico P J, Haseman J K, Dixon D. Transforming growth factor-alpha, epidermal growth factor receptor, and PCNA immunoexpression in uterine leiomyosarcomas and leiomyomas in B6C3F1 mice. Experimental and Toxicologic Pathology. 2000; 52(3): 195-200."
  32. Sato O, Wada T, Kawai A, et al. Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: A clinicopathologic study of 281 cases. Cancer. 2005; 103(9): 1881–1890.
  33. Sette G, Salvati V, Memeo L, et al. EGFR inhibition abrogates leiomyosarcoma cell chemoresistance through inactivation of survival pathways and impairment of CSC potential. PLoS One. 2012; 7(10): e46891.
  34. Moon B K, Lee Y J, Battle P, Jessup J M, Raz A, Kim H R C. Galectin-3 protects human breast carcinoma cells against nitric oxide-induced apoptosis: Implication of galectin-3 function during metastasis. The American Journal of Pathology. 2001; 159(3): 1055-1060."
  35. Liu F T, Rabinovich G A. Galectins as modulators of tumour progression. Nature Reviews Cancer. 2005; 5(1): 29-41."
  36. de Oliveira J T, Ribeiro C, Gärtner F. Role of galectin-3 in cancer metastasis. Glycobiology Insights. 2015; 5: 1-13.
  37. Ahmed H, AlSadek D M. Galectin-3 as a potential target to prevent cancer metastasis. Clinical Medicine Insights. Oncology. 2015; 9: 113-121."
  38. Kayser K, Zink S, Schneider T, et al. Benign metastasizing leiomyoma of the uterus: Documentation of clinical, immunohistochemical and lectin-histochemical data of ten cases. Virchows Arch. 2000; 437(3): 284-292."
  39. Schwarz G, Remmelink M, Decaestecker C, et al. Galectin fingerprinting in tumor diagnosis: Differential expression of galectin-3 and galectin-3 binding sites, but not galectin-1, in benign vs malignant uterine smooth muscle tumors. Am J Clin Pathol.1999;. 111(5): 623-631."
  40. Weissenbacher T, Kuhn C, Mayr D, et al. Expression of mucin-1, galectin-1 and galectin-3 in human leiomyosarcoma in comparison to leiomyoma and myometrium. Anticancer Res. 2011; 31(2): 451-457."
  41. Tsuboi K, Shimura T, Masuda N, et al.Galectin-3 expression in colorectal cancer: Relation to invasion and metastasis. Anticancer Res. 2007; 27(4B): 2289-2296.
  42. Sozen I, Arici A. Interactions of cytokines, growth factors, and the extracellular matrix in the cellular biology of uterine leiomyomata. Fertil Steril. 2002; 78(1):1-12."
  43. Lusby K, Savannah K B, Demicco E G, et al. Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: A single institution's experience. Ann Surg Oncol. 2013; 20(7): 2364-2372."
  44. Maruo T, Matsuo H, Shimomura Y, et al. Effects of progesterone on growth factor expression in human uterine leiomyoma. Steroids. 2003; 68(10): 817-824."
  45. Mackay A, Jones C, Dexter T, et al. cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells. Oncogene. 2003;. 22(17): 2680-2688.
  46. Gupta A. Galectin-3: Forms, functions, and clinical manifestations. In Gupta, G S, Gupta RK, eds. Animal lectins: Form, function and clinical applications.1st ed. New York Dordrecht London: Springer 2012; 219.
  47. Cui G, Cui M, Li Y, et al. Galectin-3 knockdown increases gefitinib sensitivity to the inhibition of EGFR endocytosis in gefitinib-insensitive esophageal squamous cancer cells. Med Oncol. 2015; 32(4):124."
  48. Nio J, Iwanaga T. Galectins in the mouse ovary: Concomitant expression of galectin-3 and progesterone degradation enzyme (20α-HSD) in the corpus luteum. J Histochem Cytochem. 2007; 55(5): 423-432.
  49. Yang H, Lei C, Cheng C, et al. The antiapoptotic effect of galectin-3 in human endometrial cells under the regulation of estrogen and progesterone. Biol Reprod. 2012; 87(2): 39, 1-7."
  50. Yang H, Yin J, Ficarrotta K, Hsu S H, Zhang W, Cheng C. Aberrant expression and hormonal regulation of galectin-3 in endometriosis women with infertility. J Endocrinol Invest. 2016; 39(7): 785-791.
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 752 Download : 377